GW Pharmaceuticals to Report Third Quarter Financial Results and Host Conference Call on 7 August, 2018
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, has received U.S.
|GW Pharmaceuticals plc
Stephen Schultz, VP Investor Relations (U.S.)
|917 280 2424 / 401 500 6570|
Source: GW Pharmaceuticals plc